JP6069492B2 - C型肝炎ウイルス阻害剤 - Google Patents

C型肝炎ウイルス阻害剤 Download PDF

Info

Publication number
JP6069492B2
JP6069492B2 JP2015509101A JP2015509101A JP6069492B2 JP 6069492 B2 JP6069492 B2 JP 6069492B2 JP 2015509101 A JP2015509101 A JP 2015509101A JP 2015509101 A JP2015509101 A JP 2015509101A JP 6069492 B2 JP6069492 B2 JP 6069492B2
Authority
JP
Japan
Prior art keywords
alkyl
compound
methyl
mmol
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015509101A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015515494A5 (enExample
JP2015515494A (ja
Inventor
ロバート マレー マッキネル,
ロバート マレー マッキネル,
ダニエル ディー. ロング,
ダニエル ディー. ロング,
Original Assignee
セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー
セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー, セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー filed Critical セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー
Publication of JP2015515494A publication Critical patent/JP2015515494A/ja
Publication of JP2015515494A5 publication Critical patent/JP2015515494A5/ja
Application granted granted Critical
Publication of JP6069492B2 publication Critical patent/JP6069492B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/081Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0816Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring comprising Si as a ring atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2015509101A 2012-04-25 2013-04-24 C型肝炎ウイルス阻害剤 Expired - Fee Related JP6069492B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261637956P 2012-04-25 2012-04-25
US61/637,956 2012-04-25
US201361773977P 2013-03-07 2013-03-07
US61/773,977 2013-03-07
PCT/US2013/037934 WO2013163270A1 (en) 2012-04-25 2013-04-24 Hepatitis c virus inhibitors

Publications (3)

Publication Number Publication Date
JP2015515494A JP2015515494A (ja) 2015-05-28
JP2015515494A5 JP2015515494A5 (enExample) 2016-04-21
JP6069492B2 true JP6069492B2 (ja) 2017-02-01

Family

ID=48227586

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015509101A Expired - Fee Related JP6069492B2 (ja) 2012-04-25 2013-04-24 C型肝炎ウイルス阻害剤

Country Status (7)

Country Link
US (2) US9066944B2 (enExample)
EP (1) EP2850072B1 (enExample)
JP (1) JP6069492B2 (enExample)
CN (1) CN104302636B (enExample)
CA (1) CA2869908C (enExample)
ES (1) ES2599665T3 (enExample)
WO (1) WO2013163270A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2624846T3 (es) * 2012-04-25 2017-07-17 Theravance Biopharma R&D Ip, Llc Compuestos de piperazina-piperidina como inhibidores del virus de la hepatitis C
GB202013383D0 (en) * 2020-08-26 2020-10-07 Givaudan Sa Process

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8303944B2 (en) 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8147818B2 (en) 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8729077B2 (en) 2008-11-28 2014-05-20 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
WO2010094977A1 (en) * 2009-02-23 2010-08-26 Arrow Therapeutics Limited Novel biphenyl compounds useful for the treatment of hepatitis c
WO2010096777A1 (en) 2009-02-23 2010-08-26 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
BRPI1010795B1 (pt) 2009-05-13 2018-12-11 Gilead Pharmasset Llc compostos antivirais, seu uso e composição farmacêutica compreendendo os mesmos
US8822700B2 (en) 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US9156818B2 (en) 2009-09-11 2015-10-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PE20130244A1 (es) * 2010-01-25 2013-03-10 Enanta Pharm Inc Inhibidores del virus de la hepatitis c
CN102918049A (zh) 2010-03-09 2013-02-06 默沙东公司 稠合三环甲硅烷基化合物及其用于治疗病毒性疾病的方法
EP2575819A4 (en) 2010-06-04 2013-11-27 Enanta Pharm Inc INHIBITORS OF HEPATITIS C VIRUS
AU2010358561B2 (en) * 2010-08-04 2016-06-02 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8697704B2 (en) * 2010-08-12 2014-04-15 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
ES2548286T3 (es) * 2010-11-04 2015-10-15 Theravance Biopharma R&D Ip, Llc Nuevos inhibidores del virus de la hepatitis C
CA2852700A1 (en) 2011-11-03 2013-05-10 Theravance, Inc. Rod-like hepatitis c virus inhibitors containing the fragment {2-[4-(biphenyl-4-yl)-1h-imidazo-2-yl]pyrrolidine-1-carbonlymethyl}amine
US8883135B2 (en) * 2012-05-03 2014-11-11 Theravance Biopharma R&D Ip, Llc Crystalline form of a pyridyl-piperazinyl hepatitis C virus inhibitor

Also Published As

Publication number Publication date
CN104302636B (zh) 2017-03-29
US20130287731A1 (en) 2013-10-31
CN104302636A (zh) 2015-01-21
US9365549B2 (en) 2016-06-14
JP2015515494A (ja) 2015-05-28
EP2850072A1 (en) 2015-03-25
US9066944B2 (en) 2015-06-30
EP2850072B1 (en) 2016-08-31
CA2869908C (en) 2018-02-20
US20150252023A1 (en) 2015-09-10
CA2869908A1 (en) 2013-10-31
WO2013163270A1 (en) 2013-10-31
ES2599665T3 (es) 2017-02-02

Similar Documents

Publication Publication Date Title
JP6082747B2 (ja) フラグメント{2−[4−(ビフェニル−4−イル)−1h−イミダゾ−2−イル]ピロリジン−1−カルボニルメチル}アミンを含む棒状c型肝炎ウイルス阻害剤
JP5891235B2 (ja) C型肝炎ウイルスの新規阻害剤
JP6069492B2 (ja) C型肝炎ウイルス阻害剤
JP6069491B2 (ja) C型肝炎ウイルス阻害剤としてのピペラジン−ピペリジン化合物
NZ623846B2 (en) Rod-like hepatitis c virus inhibitors containing the fragment {2-[4-(bi phenyl-4-yl) -1h-imidazo-2-yl] pyrrolidine-1-carbonlymethyl} amine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160303

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160303

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160829

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160831

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161128

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161220

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161226

R150 Certificate of patent or registration of utility model

Ref document number: 6069492

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees